125 related articles for article (PubMed ID: 18288922)
1. Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drug.
Bifulco M; Malfitano AM; Proto MC; Santoro A; Caruso MG; Laezza C
Anticancer Agents Med Chem; 2008 Feb; 8(2):200-4. PubMed ID: 18288922
[TBL] [Abstract][Full Text] [Related]
2. N6-isopentenyladenosine and its analogue N6-benzyladenosine induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells.
Castiglioni S; Casati S; Ottria R; Ciuffreda P; Maier JA
Anticancer Agents Med Chem; 2013 May; 13(4):672-8. PubMed ID: 23094912
[TBL] [Abstract][Full Text] [Related]
3. N6-isopentenyladenosine: a potential therapeutic agent for a variety of epithelial cancers.
Spinola M; Colombo F; Falvella FS; Dragani TA
Int J Cancer; 2007 Jun; 120(12):2744-8. PubMed ID: 17304507
[TBL] [Abstract][Full Text] [Related]
4. Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
Scrima M; Lauro G; Grimaldi M; Di Marino S; Tosco A; Picardi P; Gazzerro P; Riccio R; Novellino E; Bifulco M; Bifulco G; D'Ursi AM
J Med Chem; 2014 Sep; 57(18):7798-803. PubMed ID: 25184810
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics and analogues of the antitumour agent N6-isopentenyladenosine.
Colombo F; Falvella FS; De Cecco L; Tortoreto M; Pratesi G; Ciuffreda P; Ottria R; Santaniello E; Cicatiello L; Weisz A; Dragani TA
Int J Cancer; 2009 May; 124(9):2179-85. PubMed ID: 19123479
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells.
Laezza C; Malfitano AM; Di Matola T; Ricchi P; Bifulco M
Mol Carcinog; 2010 Oct; 49(10):892-901. PubMed ID: 20672320
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative activity of N6-isopentenyladenosine on MCF-7 breast cancer cells: cell cycle analysis and DNA-binding study.
Rajabi M; Signorelli P; Gorincioi E; Ghidoni R; Santaniello E
DNA Cell Biol; 2010 Nov; 29(11):687-91. PubMed ID: 20818975
[TBL] [Abstract][Full Text] [Related]
8. N6-Isopentenyladenosine promoted HeLa cell apoptosis through inhibitions of AKT and transforming growth factor β-activated kinase 1 activation.
Li M; Qi Y; Wei J; Lu L; Zhao X; Zhou L
Tumour Biol; 2017 Mar; 39(3):1010428317695966. PubMed ID: 28345459
[TBL] [Abstract][Full Text] [Related]
9. N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.
Ranieri R; Ciaglia E; Amodio G; Picardi P; Proto MC; Gazzerro P; Laezza C; Remondelli P; Bifulco M; Pisanti S
Cell Death Differ; 2018 Feb; 25(2):353-367. PubMed ID: 29027991
[TBL] [Abstract][Full Text] [Related]
10. N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation.
Laezza C; Notarnicola M; Caruso MG; Messa C; Macchia M; Bertini S; Minutolo F; Portella G; Fiorentino L; Stingo S; Bifulco M
FASEB J; 2006 Mar; 20(3):412-8. PubMed ID: 16507758
[TBL] [Abstract][Full Text] [Related]
11. Novel isopentenyladenosine analogues: synthesis, characterization, and evaluation of antiproliferative activity on bladder carcinoma cells.
Ottria R; Casati S; Maier JA; Mariotti M; Ciuffreda P
Nucleosides Nucleotides Nucleic Acids; 2009 Aug; 28(8):736-51. PubMed ID: 20183613
[TBL] [Abstract][Full Text] [Related]
12. Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines.
Ciaglia E; Laezza C; Abate M; Pisanti S; Ranieri R; D'alessandro A; Picardi P; Gazzerro P; Bifulco M
Int J Cancer; 2018 Jan; 142(1):176-190. PubMed ID: 28884474
[TBL] [Abstract][Full Text] [Related]
13. The modified base isopentenyladenosine and its derivatives in tRNA.
Schweizer U; Bohleber S; Fradejas-Villar N
RNA Biol; 2017 Sep; 14(9):1197-1208. PubMed ID: 28277934
[TBL] [Abstract][Full Text] [Related]
14. N6-isopentenyladenosine a new potential anti-angiogenic compound that targets human microvascular endothelial cells in vitro.
Castiglioni S; Romeo V; Casati S; Ottria R; Perrotta C; Ciuffreda P; Maier JAM
Nucleosides Nucleotides Nucleic Acids; 2018; 37(10):533-545. PubMed ID: 30465624
[TBL] [Abstract][Full Text] [Related]
15. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.
Ciaglia E; Abate M; Laezza C; Pisanti S; Vitale M; Seneca V; Torelli G; Franceschelli S; Catapano G; Gazzerro P; Bifulco M
Int J Cancer; 2017 Feb; 140(4):959-972. PubMed ID: 27813087
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activity of N(6)-isopentenyladenosine on HCT-15 colon carcinoma cell line.
Rajabi M; Mehrzad J; Gorincioi E; Santaniello E
Nucleic Acid Ther; 2011 Oct; 21(5):355-8. PubMed ID: 22004416
[TBL] [Abstract][Full Text] [Related]
17. Chemical modification of the plant isoprenoid cytokinin N(6)-isopentenyladenosine yields a selective inhibitor of human enterovirus 71 replication.
Tararov VI; Tijsma A; Kolyachkina SV; Oslovsky VE; Neyts J; Drenichev MS; Leyssen P; Mikhailov SN
Eur J Med Chem; 2015 Jan; 90():406-13. PubMed ID: 25461889
[TBL] [Abstract][Full Text] [Related]
18. N6-isopentenyladenosine affects cAMP-dependent microfilament organization in FRTL-5 thyroid cells.
Laezza C; Migliaro A; Cerbone R; Tedesco I; Santillo M; Garbi C; Bifulco M
Exp Cell Res; 1997 Jul; 234(1):178-82. PubMed ID: 9223384
[TBL] [Abstract][Full Text] [Related]
19. Presence and source of free isopentenyladenosine in yeasts.
Laten HM; Zahareas-Doktor S
Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1113-5. PubMed ID: 3883351
[TBL] [Abstract][Full Text] [Related]
20. N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.
Ciaglia E; Pisanti S; Picardi P; Laezza C; Sosa S; Tubaro A; Vitale M; Gazzerro P; Malfitano AM; Bifulco M
Pharmacol Res; 2014 Nov; 89():1-10. PubMed ID: 25063359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
